This session will feature four PRO/CON debates on cutting edge topics in interstitial lung disease. Topics will include cryobiopsy in fibrotic lung disease, use of the envisia molecular classifier, whether IPF is truly a distinct clinical entity and management of non-IPF progressive pulmonary fibrosis.
CME credits and/or Certificates of Completion are not provided for this session.
1- Understand the risks and benefits of transbronchial lung cryobiopsy
2- Apply use of a genomic classifier from transbronchial biopsy specimens in clinical practice after discussion of yield and limitations
3- Appreciate the importance of 1) need to make a diagnosis of ILD early, before the disease progresses to severe fibrotic stages such as usual interstitial pneumonia and 2) treat with appropriate disease modifying agents
Marlies Wijsenbeek, MD, PhD: PRO: IPF Is a Distinct Clinical Entity
Ganesh Raghu, MD: CON: IPF Is a Distinct Clinical Entity
Manuela Funke, MD: PRO: A Genomic Classifier From Transbronchial Lung Biopsy Specimens Is Useful in UIP Diagnosis
Justin Oldham, MD, MS: CON: A Genomic Classifier From Transbronchial Lung Biopsy Specimens Is Useful in UIP Diagnosis
Sonye K. Danoff, MD, PhD, ATSF: PRO: Transbronchial Cryobiopsy Is Useful for Histopathologic Diagnosis of Fibrotic Interstitial Lung Disease
Lauren K. Troy, PhD, MBBS, BMedSci, FRACP: CON: Transbronchial Cryobiopsy Is Useful for Histopathologic Diagnosis of Fibrotic Interstitial Lung Disease
You can save 20% today by joining the ATS. Join more than 16,000 healthcare providers and researchers as a member of the American Thoracic Society today. As an ATS member, you’ll gain access to cutting-edge science, collaboration opportunities, discounts on the annual ATS International Conference, and resources to share with patients. The ATS offers multiple ways to get involved, from Assembly membership to in-person networking opportunities, as well as an online community offered through DocMatter. Join the ATS Today!